NCT03192150View on ClinicalTrials.gov

2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

PHASE3CompletedINTERVENTIONAL

Enrollment

246

Participants

Timeline

Start Date

January 3, 2018

Primary Completion Date

November 18, 2019

Study Completion Date

November 18, 2019

Conditions

Inflammation and Pain Associated With Cataract Surgery

Interventions

DRUG

ISV-305

Dexamethasone in DuraSite® 2 twice daily for 16 days

OTHER

Vehicle

Vehicle twice daily for 16 days

Trial Locations (1)

78731

Clinical Research Center, Austin

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT03192150 - 2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery | Biotech Hunter | Biotech Hunter